Skip to content

Frontlight ResearchEarly access

Institution

McGill University Health Centre

Montreal, CanadaWebsite

Also known as: Centre universitaire de santé McGill · MUHC

183running trials
101closed trials
31,548publications (OpenAlex)

Running trials

Not yet recruiting
RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial
NCT07625930· Phase 2· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Not yet recruiting
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
NCT07877298· University Hospital Muenster· Source
Not yet recruiting
18F-FDG PET/CT for Diagnosis of Diabetic Foot Osteomyelitis
NCT07828691· Jewish General Hospital· Source
Recruiting
Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
NCT07282210· Phase 2· Biossil Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
NCT07541170· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
The CANadian EXAcerbation of COPD Trial
NCT07850648· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161· Phase 3· Takeda· Source
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200· Phase 3· Incyte Corporation· Source
Not yet recruiting
Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy
NCT07634237· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
NCT07284511· Phase 2/3· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07571200· Phase 1· Eli Lilly and Company· Source
Recruiting
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07571174· Phase 1· Eli Lilly and Company· Source
Recruiting
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
NCT07483658· CHU de Quebec-Universite Laval· Source
Recruiting
Randomized Controlled Trial- Ablation Strategy for Paroxysmal Atrial Fibrillation - Trigger and Substrate Guided Wide Area Radiofrequency Ablation Compared to Pulsed Field Ablation Pulmonary Vein Isolation
NCT04823299· Ottawa Heart Institute Research Corporation· Source
Recruiting
This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling.
NCT07739784· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
NCT07309614· Phase 3· Université de Sherbrooke· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
NCT07094048· Phase 4· CHU de Quebec-Universite Laval· Source
Recruiting
Evaluating the Feasibility of elleFA App Implementation
NCT06452407· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232· Phase 3· Revolution Medicines, Inc.· Source
Recruiting
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· Phase 3· Pfizer· Source
Recruiting
Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough
NCT06858748· McMaster University· Source
Not yet recruiting
A Patient Portal and PROMs to Improve Health Problem Detection and Retention in HIV Care: The DRHIVe Study
NCT06928961· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Active, not recruiting
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037· Phase 2· Vertex Pharmaceuticals Incorporated· Source
Not yet recruiting
REDO-AF: Randomized Evaluation of Dual Options for AF Re-intervention
NCT07245147· Jacqueline Joza· Source
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173· Phase 2· Eli Lilly and Company· Source
Recruiting
Helping Couples Communicate Better: Does This Help Persons With Type 2 Diabetes Respond Better to a Step Count Prescription?
NCT07142512· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499· Phase 1· Pfizer· Source
Recruiting
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
NCT07112339· Phase 4· Novo Nordisk A/S· Source
Active, not recruiting
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
NCT07076199· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· Phase 3· Pfizer· Source
Active, not recruiting
Combined Pulsed Field and Radiofrequency Energy for Ablation of Ventricular Tachycardia
NCT06816368· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
NCT06337838· Phase 3· Hamilton Health Sciences Corporation· Source
Recruiting
COgnitioN With VERiciGuat Evaluation in Heart Failure
NCT06601465· Phase 2· University of Alberta· Source
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Predicting Acute Exacerbations of COPD Using Wearable Devices and Remote Monitoring Technology With AI/ML Models
NCT06802003· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Enrolling by invitation
Whole Heart Radiotherapy for End-stage Heart Failure
NCT06299176· Phase 1· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
NCT06843447· Phase 1/2· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT06665165· Phase 1· Amylyx Pharmaceuticals Inc.· Source
Recruiting
The Dragon PLC Trial (DRAGON-PLC)
NCT06914648· Maastricht University· Source
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
NCT06453486· Phase 2· University Health Network, Toronto· Source
Recruiting
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
NCT05272826· Phase 2· Canadian Myeloma Research Group· Source

Showing 50 of 183.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Completed
Assessing Optimal Inhaler Strategies During Acute Exacerbations of COPD (AECOPDs) Using Oscillometry
NCT06495047· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Completed
The Effects of Oscillatory Positive Expiratory Pressure (OPEP) Therapy in Patients With COPD
NCT06614959· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Withdrawn
Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia
NCT06560346· Friedreich's Ataxia Research Alliance· Source
Recruiting
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505· Phase 3· AbbVie· Source
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245· Phase 3· OSE Immunotherapeutics· Source
Withdrawn
Evaluating Tibolone Add-back in Patients With Endometriosis and Fibroids
NCT05568940· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Terminated
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
NCT06524739· Phase 3· CSL Behring· Source
Terminated
A Study of SGN-MesoC2 in Advanced Solid Tumors
NCT06466187· Phase 1· Seagen, a wholly owned subsidiary of Pfizer· Source
Completed
Oral Supplementation During PR Participation in COPD
NCT06324214· Phase 2· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Completed
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAFOUS
NCT06272981· Biosense Webster, Inc.· Source
Completed
A Multimodal Wearable Platform for Heart Failure Disease Stratification
NCT06335264· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788· Phase 3· Merck Sharp & Dohme LLC· Source
Terminated
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
NCT05712694· Phase 3· Polaris Group· Source
Completed
Patient Perspective on Climate Impact of Inhalers
NCT06097507· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Terminated
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
NCT06032546· Phase 2· AbbVie· Source
Completed
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT06036836· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
NCT05813275· Phase 3· Apnimed· Source
Completed
A Study For Treatment of Paroxysmal Atrial Fibrillation (PAF) With the OMNYPULSE Catheter and the TRUPULSE Generator
NCT05971693· Biosense Webster, Inc.· Source
Completed
Measuring Lung Mechanics in Patients with COPD Using the REOM Handheld Portable Device
NCT05913323· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Recruiting
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
NCT05727176· Phase 2· Taiho Oncology, Inc.· Source
Completed
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source
Terminated
Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers
NCT05860296· Phase 1/2· SignalChem Lifesciences Corporation· Source
Completed
A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada
NCT05571137· Takeda· Source
Completed
Randomized Ablation-based AF Rhythm-control Versus Rate-control in Patients With HF and High-burden AF Extend
NCT05118893· Anthony Tang· Source
Recruiting
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394· Phase 3· AbbVie· Source
Completed
Wearable Devices in the Recovery Phase of Acute Exacerbations of COPD (AECOPDs)
NCT05776654· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Completed
Multifaceted Intervention Using Telehealth to Reduce the Risk of Falls and Fractures in Older Men
NCT05927623· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Completed
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
NCT05686070· Phase 3· Bayer· Source
Completed
Safety and Efficacy of Canagliflozin in Advanced CKD
NCT05309785· Phase 4· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Completed
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT05287113· Phase 2· Incyte Biosciences International Sàrl· Source
Completed
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
NCT05327127· Phase 2· Kowa Research Institute, Inc.· Source
Completed
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Letermovir in ART-treated HIV-infected Persons
NCT05362916· Jean-Pierre Routy· Source
Completed
IBD Neoplasia Surveillance RCT
NCT05809999· Ottawa Hospital Research Institute· Source
Completed
ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES
NCT05280067· Phase 2· Zetagen Therapeutics, Inc· Source
Terminated
Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
NCT04638582· Phase 2· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Completed
DECIDE-CV Using AI
NCT05482958· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Completed
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
NCT05180240· Phase 2· Cardiol Therapeutics Inc.· Source
Completed
Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
NCT05446870· Phase 2· Merck Sharp & Dohme LLC· Source
Completed
Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
NCT05405114· Phase 2· Novo Nordisk A/S· Source
Completed
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
NCT05353985· Phase 2· Takeda· Source
Terminated
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source
Completed
Prehabilitation for Patients Awaiting Liver Transplantation
NCT05237583· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Terminated
Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease
NCT05049525· Phase 2· Montreal Heart Institute· Source
Terminated
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
NCT05070845· Phase 2· Pfizer· Source
Completed
Keeping in Touch (KiT) With Youth as They Transition to Adult Type 1 Diabetes Care
NCT05434754· The Hospital for Sick Children· Source
Completed
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
NCT05143957· Phase 2· Ionis Pharmaceuticals, Inc.· Source
Completed
EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement
NCT05118308· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source
Terminated
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
NCT05085366· Phase 3· ModernaTX, Inc.· Source
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223· Phase 1· Hoffmann-La Roche· Source

Showing 50 of 101.

Registry name variants (70)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

McGill University Health Centre
Montreal, Quebec H4A 3J1
148 trials
McGill University Health Center
Montreal, Quebec H4A 3J1
57 trials
McGill University Health Centre
Québec, H4A 3J1
3 trials
- NCT06524739Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS
- NCT05186974Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
- NCT05171049A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
McGill University Health Centre/Glen Site/Cedars Cancer Centre
Montreal, Quebec H4A 3J1
2 trials
- NCT05287113Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- NCT02723994A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
McGill University Health Centre, Montreal
Montreal, H4A 3J1
2 trials
- NCT07850648The CANadian EXAcerbation of COPD Trial
  Contact: Bryan A. Ross
- NCT06914648The Dragon PLC Trial (DRAGON-PLC)
  Contact: Peter Metrakos, Prof. Dr.
McGill University Health Centre - Montreal Neurological Institute
Montreal, Quebec H9R 2Y2
2 trials
- NCT06560346Understanding the Natural History Early in the Course or Presentation of Friedreich Ataxia
- NCT06016946Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
  Contact: Christian Rampal
McGill University Health Centre (Site 0100)
Montreal, Quebec H4A 3J1
2 trials
- NCT06843447A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
  Contact: Study Coordinator
- NCT06077760A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
McGill University Health Centre (Site 0105)
Montreal, Quebec H4A 3J1
2 trials
- NCT06312137A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
  Contact: Study Coordinator
- NCT04221945Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
McGill University Health Centre (Site 0204)
Montreal, Quebec H4A 3J1
2 trials
- NCT06841354A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
  Contact: Study Coordinator
- NCT06305754Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
McGill University Health Centre (Site 0207)
Montreal, Quebec H4A 3J1
2 trials
- NCT04456699Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
- NCT03867084Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
McGill University Health Centre (Site 0210)
Montreal, Quebec H4A 3J1
2 trials
- NCT04624204Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
- NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
McGill University Health Centre (Site 0502)
Montreal, Quebec H4A 3J1
2 trials
- NCT06824467A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
  Contact: Study Coordinator
- NCT05116189Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
McGill University Health Centre (Site 0604)
Montreal, Quebec H4A 3J1
2 trials
- NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
  Contact: Study Coordinator
- NCT06036836Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Cedars Cancer Center, McGill University Health Centre
Montreal, Quebec H4A3J1
1 trial
- NCT05258422Stereotactic Arrhythmia Radioablation for Ventricular Tachycardia (StAR-VT)
Centre universitaire de santé McGill - McGill University Health Centre
Montreal, Quebec H4A 3J1
1 trial
- NCT05169112Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy
  Contact: Rodney Breau, Dr.
Chronic Viral Illness Service, Division of Infectious Disease, Department of Medicine, McGill University Health Centre - Glen Site
Montreal, Quebec
1 trial
- NCT06928961A Patient Portal and PROMs to Improve Health Problem Detection and Retention in HIV Care: The DRHIVe Study
  Contact: Bertrand P Lebouché, MD, PhD
McGill University Department of Oncology / McGill University Health Centre
Montreal, Quebec H4A 3J1
1 trial
- NCT04499924Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
McGill University Health Center - Glen site
Montreal, Quebec H4A3J1
1 trial
- NCT04752722LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
  Contact: W Kassouf
McGill University Health Center McGill University
Montreal, Quebec H3A 1A1
1 trial
- NCT05353985A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
McGill University Health Center - Neurology Department
Montreal, Quebec H3A 2B4
1 trial
- NCT05686070A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
McGill University Health Center - Research Institute-CVIS Clinical Research Unit (Site 5702)
Montreal, Quebec H4A 3J1
1 trial
- NCT04233879Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)
McGill University Health Centre - Cedars Cancer Center - Oncology
Montreal, Quebec H4A-3J1
1 trial
- NCT03778931Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
McGill University Health Centre - Centre for Innovative Medicine
Montreal, Quebec H4A 3J1
1 trial
- NCT06665165AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
  Contact: Maria Gobbo
McGill University Health Centre_CUSM
Montreal, Quebec H4A 3J1
1 trial
- NCT05327647A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
  Contact: Wassim Kassouf, MDCM
McGill University Health Centre, Glen site Cedars Cancer Center
Montreal, Quebec H4A 3J1
1 trial
- NCT02788461Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
McGill University Health Centre - Glen Site, Centre For Innovative Medicine
Montreal, Quebec H4A 3J1
1 trial
- NCT07623200A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
McGill University Health Centre - Glen Site /ID# 222519
Montreal, Quebec H4A 3J1
1 trial
- NCT04401748Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
McGill University Health Centre - Glen Site /ID# 222614
Montreal, Quebec H4A 3J1
1 trial
- NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
McGill University Health Centre - Glen Site /ID# 247271
Montreal, Quebec H4A 3J1
1 trial
- NCT05711394A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
McGill University Health Centre - Glen Site. /ID# 256992
Montreal, Quebec H4A 3J1
1 trial
- NCT06032546A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382
McGill University Health Centre - Glen Site /ID# 269084
Montreal, Quebec H4A 3J1
1 trial
- NCT05456685Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
McGill University Health Centre - Glen Site /ID# 269313
Montreal, Quebec H4A 3J1
1 trial
- NCT06365853A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
McGill University Health Centre - Glen Site. /ID# 269389
Montreal, Quebec H4A 3J1
1 trial
- NCT05445778Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
McGill University Health Centre - Glen Site /ID# 270662
Montreal, Quebec H4A 3J1
1 trial
- NCT06810505A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
McGill University Health Centre - Glen Site. /ID# 271275
Montreal, Quebec H4A 3J1
1 trial
- NCT06318273A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
McGill University Health Centre (Quebec)
Montreal, Quebec H4A 311
1 trial
- NCT05712694Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
McGill University Health Centre (Site 0023)
Montreal, Quebec H4A 3J1
1 trial
- NCT06428409A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
  Contact: Toll Free Number
McGill University Health Centre (Site 0052)
Montreal, Quebec H4A 3J1
1 trial
- NCT03713593Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
McGill University Health Centre (Site 0061)
Montreal, Quebec H4A 3J1
1 trial
- NCT03040999Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
McGill University Health Centre (Site 0062)
Montreal, Quebec H4A 3J1
1 trial
- NCT03553836Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
McGill University Health Centre (Site 0103)
Montreal, Quebec H4A 3J1
1 trial
- NCT06422143Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
  Contact: Study Coordinator
McGill University Health Centre (Site 0106)
Montreal, Quebec H4A 3J1
1 trial
- NCT06136559A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
  Contact: Study Coordinator
McGill University Health Centre (Site 0111)
Montreal, Quebec H4A 3J1
1 trial
- NCT03425643Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
McGill University Health Centre (Site 0123)
Montreal, Quebec H4A 3J1
1 trial
- NCT03924895Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
McGill University Health Centre (Site 0179)
Montreal, Quebec H4A 3J1
1 trial
- NCT04003636Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
McGill University Health Centre (Site 0200)
Montreal, Quebec H4A 3J1
1 trial
- NCT06170788Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
  Contact: Toll Free Number
McGill University Health Centre (Site 0201)
Montreal, Quebec H4A 3J1
1 trial
- NCT06356311A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
McGill University Health Centre (Site 0202)
Montreal, Quebec H4A 3J1
1 trial
- NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Contact: Study Coordinator
McGill University Health Centre (Site 0206)
Montreal, Quebec H4A 3J1
1 trial
- NCT04199104A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
McGill University Health Centre (Site 0208)
Montreal, Quebec H4A 3J1
1 trial
- NCT03675737Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
McGill University Health Centre (Site 0209)
Montreal, Quebec H4A 3J1
1 trial
- NCT05008224Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
McGill University Health Centre (Site 0301)
Montreal, Quebec H4A 3J1
1 trial
- NCT05446870Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
McGill University Health Centre (Site 0314)
Montreal, Quebec H4A 3J1
1 trial
- NCT05508867A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)
McGill University Health Centre (Site 0400)
Montreal, Quebec H4A 3J1
1 trial
- NCT05877547A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
McGill University Health Centre (Site 0404)
Montreal, Quebec H4A 3J1
1 trial
- NCT03884101Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)
McGill University Health Centre (Site 0418)
Montreal, Quebec H4A 3J1
1 trial
- NCT03829332Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)
McGill University Health Centre (Site 0505)
Montreal, Quebec H4A 3J1
1 trial
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
McGill University Health Centre (Site 0516)
Montreal, Quebec H4A 3J1
1 trial
- NCT07318558A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
  Contact: Study Coordinator
McGill University Health Centre (Site 0602)
Montreal, Quebec H4A 3J1
1 trial
- NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
  Contact: Study Coordinator
McGill University Health Centre (Site 0651)
Montreal, Quebec H4A 3J1
1 trial
- NCT03820986Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)
McGill University Health Centre (Site 1101)
Montreal, Quebec H4A 3J1
1 trial
- NCT03179436Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
McGill University Health Centre (Site 1103)
Montreal, Quebec H4A 3J1
1 trial
- NCT06623422A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
  Contact: Study Coordinator
McGill University Health Centre (Site 1306)
Montreal, Quebec H4A 3J1
1 trial
- NCT05766501A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
McGill University Health Centre (Site 1404)
Montreal, Quebec H4A 3J1
1 trial
- NCT06132958Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
McGill University Health Centre (Site 3005)
Montreal, Quebec H4A 3J1
1 trial
- NCT04634877Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
McGill University Health Centre - Site #304
Montreal, Quebec H4A 3J1
1 trial
- NCT05248646Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
McGill University Health Centre (Site 3709)
Montreal, Quebec H4A 3J1
1 trial
- NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
McGill University Health Centre (Site 4000)
Montreal, Quebec H4A 3J1
1 trial
- NCT06459180A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
McGill University University Health Centre
Montreal, Quebec H3H 2R9
1 trial
- NCT06337838Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial
  Contact: Lin Jawhar
Montreal Neurological Institute - McGill University Health Centre
Montreal, Quebec H3A 2B4
1 trial
- NCT02780024Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM

Conditions

Diseases this institution publishes on or runs trials for.

Institution data: ROR 04cpxjv19 (CC0-1.0)Updated 14 Nov 2026

Report an error

McGill University Health Centre: trials and research groups – Frontlight Research